Iran unveils indigenous precision drug delivery technology for cancer treatment

Iranian researchers at a domestic knowledge-based company have developed an advanced medical device that enables highly targeted drug delivery to cancer tumors, using fully localized microfluidics technology.

The achievement marks a significant step forward in Iran’s nanomedicine and biotechnology sectors.

According to the Iranian Vice Presidency for Science, Technology and Knowledge-Based Economy, the device was developed by the company “Nanocynthesis Therapeutic Optimization System,” which has successfully broken the monopoly on producing drug nanocarriers.

The system is based on microfluidic technology, a core method used in the production of mRNA vaccines such as those by Pfizer and Moderna.

Mohammad Javad Javid, the company’s sales director, said the project initially aimed to encapsulate mRNA vaccines inside lipid nanoparticles (LNPs), a process that requires highly precise equipment.
He explained that the technology has broader medical applications, particularly in treating hard-to-cure diseases such as cancer.

One of the main challenges in cancer therapy is drug loss in the body and damage to healthy tissues. The Iranian-made device produces smart nanocarriers that deliver medication directly to tumors, reducing drug dosage and significantly minimizing side effects.

The system also offers major economic advantages.
While comparable foreign devices cost about $100,000, the Iranian model is priced at nearly one-twentieth of that amount and features reusable microchips.